Analyst Consensus ?
ConsensusBuy29 ratings
Bullish1551.7%
Neutral1448.3%
Bearish00.0%
Revvity, Inc. · RVTY · FY2026 Q1 · Calendar Q2 2026
Revvity Beats Q1 Estimates, Divests China Diagnostics, Raises Guidance
Revvity's Q1 FY2026 results exceeded consensus, with adjusted EPS of $1.06 versus a $1.02 estimate and revenue of $711.1 million versus $704.1 million, on 3% organic growth and 23.6% adjusted operating margins. The defining strategic move of the quarter is the planned divestiture of the China immunodiagnostics business -- retaining a minority stake with a 2027 closing target -- which management expects to lift pro-forma growth by ~100 bps and margins by ~30 bps. AI-driven software platforms (Xynthetica, BioDesign, LabGistics) are gaining traction with 40% YoY SaaS ARR growth, though a 20% Q2 sequential decline in software revenue is expected. The market responded favorably with a 6.7% move on the report and 9.5% subsequent drift. Management raised full-year guidance.
Reported Before market openNYSEHealthcare
$12.67B market cap
100quality score
Company context
Snapshot as of publicationRevvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers.…
Earnings scorecard
Reported versus consensus
Reported EPS
$1.06
Consensus $1
EPS surprise
+3.9%
Reported versus consensus
Reported revenue
$711.1M
Consensus $704.1M
Revenue surprise
+1.0%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$112.54Current
$95Low
$118.65Average
$140High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 6, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | May 7, 2026 |
| TD Cowen | Buy | Buy | Maintain | May 6, 2026 |
| Stifel | Hold | Hold | Maintain | May 6, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | May 6, 2026 |
| Baird | Outperform | Outperform | Maintain | May 4, 2026 |
| Goldman Sachs | Neutral | Neutral | Maintain | Apr 14, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Feb 3, 2026 |
| Jefferies | Hold | Hold | Maintain | Feb 3, 2026 |
| B of A Securities | Buy | Buy | Maintain | Sep 22, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Jul 29, 2025 |
| UBS | Buy | Neutral | Upgrade | May 1, 2025 |
| Keybanc | Overweight | Overweight | Maintain | Feb 3, 2025 |
| Bernstein | Outperform | Outperform | Maintain | Nov 5, 2024 |
| Leerink Partners | Outperform | Outperform | Maintain | Oct 17, 2024 |
| Citigroup | Buy | Buy | Maintain | Jul 30, 2024 |
| Cowen & Co. | Outperform | Market Perform | Upgrade | Dec 5, 2022 |
| Credit Suisse | Neutral | Neutral | Maintain | Nov 13, 2022 |
| Needham | Buy | Buy | Maintain | Nov 8, 2020 |
| CFRA | Hold | Hold | Maintain | May 5, 2020 |
| Piper Sandler | Neutral | Overweight | Downgrade | Oct 30, 2019 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jan 2, 2019 |
| Janney Montgomery Scott | Neutral | Buy | Downgrade | Nov 1, 2018 |
| Deutsche Bank | Hold | Hold | Maintain | Apr 8, 2018 |
| Mizuho | Neutral | Buy | Downgrade | Aug 4, 2016 |
| Wedbush | Neutral | Outperform | Downgrade | Dec 2, 2015 |
| ISI Group | Neutral | Buy | Downgrade | Apr 8, 2014 |
| Macquarie | Outperform | Neutral | Upgrade | Dec 9, 2013 |
| CLSA | Buy | Outperform | Maintain | Jan 16, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $112.54. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Evercore ISI | Vijay Kumar | $125 | $111.66 | +11.1% | Jul 6, 2026 |
| Bernstein | Analyst unavailable | $115 | $113.53 | +2.2% | Jun 26, 2026 |
| Stifel Nicolaus | Analyst unavailable | $100 | $92.3 | -11.1% | May 6, 2026 |
| Robert W. Baird | Catherine Ramsey Schulte | $117 | $92.3 | +4.0% | May 6, 2026 |
| Robert W. Baird | Analyst unavailable | $125 | $86.68 | +11.1% | May 4, 2026 |
| Barclays | Luke Sergott | $95 | $92.64 | -15.6% | Apr 14, 2026 |
| Robert W. Baird | Catherine Ramsey Schulte | $129 | $103.89 | +14.6% | Feb 3, 2026 |
| Cowen & Co. | Analyst unavailable | $124 | $106.97 | +10.2% | Feb 3, 2026 |
| Evercore ISI | Analyst unavailable | $118 | $107.09 | +4.9% | Feb 3, 2026 |
| Barclays | Analyst unavailable | $118 | $107.09 | +4.9% | Feb 3, 2026 |
| Jefferies | Analyst unavailable | $105 | $107.05 | -6.7% | Feb 2, 2026 |
| Wells Fargo | Brandon Couillard | $107 | $100.46 | -4.9% | Dec 15, 2025 |
| Barclays | Luke Sergott | $115 | $100.46 | +2.2% | Dec 15, 2025 |
| Goldman Sachs | Evie Koslosky | $105 | $99.79 | -6.7% | Dec 9, 2025 |
| Robert W. Baird | Analyst unavailable | $123 | $97.74 | +9.3% | Oct 28, 2025 |
| Barclays | Analyst unavailable | $105 | $97.16 | -6.7% | Oct 28, 2025 |
| Evercore ISI | Analyst unavailable | $108 | $95.88 | -4.0% | Oct 27, 2025 |
| Robert W. Baird | Catherine Ramsey Schulte | $122 | $98.64 | +8.4% | Oct 24, 2025 |
| Barclays | Analyst unavailable | $100 | $91.76 | -11.1% | Oct 2, 2025 |
| Raymond James | Andrew Cooper | $140 | $116.6 | +24.4% | Jan 21, 2025 |
| Bernstein | Eve Burstein | $130 | $113.88 | +15.5% | Jan 10, 2025 |
| KeyBanc | Paul Knight | $132 | $124.82 | +17.3% | Nov 4, 2024 |
| Barclays | Luke Sergott | $140 | $122.91 | +24.4% | Oct 15, 2024 |
| Bank of America Securities | Derik de Bruin | $127 | $125.59 | +12.8% | Jul 30, 2024 |
| Jefferies | Tycho Peterson | $125 | $125.29 | +11.1% | Jul 29, 2024 |
| Stifel Nicolaus | Daniel Arias | $110 | $120.16 | -2.3% | Jul 29, 2024 |
| Citigroup | Patrick Donnelly | $135 | $120.16 | +20.0% | Jul 29, 2024 |
| Evercore ISI | Vijay Kumar | $126 | $120.16 | +12.0% | Jul 29, 2024 |
| UBS | Dan Leonard | $120 | $105.02 | +6.6% | Apr 29, 2024 |
Track every rating change on RVTY the moment it posts. Free to start.
Start freeMarket reaction
prior-close to event-session close
Stock move
+6.7%
Event window
SPY move
+0.8%
Same window
Abnormal move
+5.9%
Stock minus SPY
Volume
1.9×
Versus trailing sessions
Subsequent drift
+9.5%
Up to 20 sessions
RVTYSPY benchmark
Follow RVTY with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Q1 FY2026 produced adjusted EPS of $1.06 (vs. $1.02 estimate) on revenue of $711.1 million (vs. $704.1 million estimate), reflecting 3% organic growth and 23.6% adjusted operating margins. The company announced a strategic divestiture of its China immunodiagnostics business with a retained minority stake and 2027 closing target. SaaS ARR grew 40% year-over-year, but management guided to a 20% sequential decline in Q2 software revenue due to seasonality. Life Sciences and reproductive health diagnostics posted double-digit organic growth. Capex outlook shifted from stable to decreasing.
Guidance delta
Guidance sentiment shifted from maintained (Q4 FY2025) to raised. The company reaffirmed full-year 2026 targets of 2-3% organic growth, revenue of $2.96-$2.99 billion, and adjusted EPS of $5.35-$5.45. The pro-forma operating margin target was lifted to 28.4% from the prior 28%, reflecting the China divestiture's margin benefit and the completion of cost-efficiency programs by mid-year.
Key takeaways
- Q1 adjusted EPS of $1.06 beat the $1.02 consensus by 3.9%; revenue of $711.1 million exceeded estimates by 1.0%.
- Strategic divestiture of China immunodiagnostics with retained minority stake and 2027 closing target improves pro-forma growth (+100 bps) and margin (+30 bps).
- SaaS ARR grew 40% year-over-year, though a 20% Q2 sequential decline in software revenue is expected due to seasonality.
- Life Sciences and reproductive health diagnostics posted double-digit organic growth, offsetting weaker pharma and academic spending.
- Pro-forma operating margin target raised to 28.4% from 28%, driven by cost-efficiency programs and the China divestiture.
Management priorities
- Execute the China immunodiagnostics divestiture with a planned 2027 closing and redeploy proceeds through share buybacks.
- Launch BioDesign at an upcoming industry trade show and roll out LabGistics later in 2026 as the AI-first drug-discovery offering.
- Complete cost-efficiency programs by mid-year to deliver the margin uplift toward the 28.4% pro-forma target.
- Continue expanding the Opera Phenix OptIQ system to capture high-content screening demand.
- Maintain disciplined capital allocation, including share repurchases funded by divestiture proceeds.
Related earnings events
HealthcareSources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-31T14:51:27.490647+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-31T14:51:27.487828+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.